For patients undergoing prostate radiotherapy, acute toxicity is associated with late toxicity and decrement in quality of ...
Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.
H.C. Wainwright raised the firm’s price target on Kura Oncology (KURA) to $40 from $37 and keeps a Buy rating on the shares. The firm says the ...
Wedbush analyst Robert Driscoll raised the firm’s price target on Kura Oncology (KURA) to $36 from $34 and keeps an Outperform rating on the ...
Healio will present its fourth annual Disruptive Innovators Awards for oncology/hematology this spring ... with relapsed or refractory B-lineage acute lymphoblastic leukemia, findings presented ...
Syndax Pharma (SNDX) stock rose after Kura Oncology (KURA) posted a mid-stage trial win for a leukemia drug is similar to ...
Men with prostate cancer are living longer than ever, and our goal is to reduce the risk of late toxicities, such as difficulty urinating or rectal bleeding, that can impact a patient’s quality of ...